ORAL MUCOSITIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Oral Mucositis Market Size and Forecast – 2025 to 2032

The global oral mucositis market is estimated to be valued at USD 1.72 Bn in 2025 and is expected to reach USD 2.84 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032. This growth is driven by increasing incidences of cancer and the rising adoption of chemotherapy and radiotherapy treatments that often lead to oral mucositis as a side effect. The expanding awareness of oral care and the development of novel therapeutic options also contribute to the market’s steady expansion.

Key Takeaways of the Global Oral Mucositis Market

• Chemotherapy-induced oral mucositis segment is expected to account for the largest share of the global oral mucositis market at 51.2% hare in 2025.
• Within treatment types, the barrier/coating agents (gels, mouthwashes, sprays, films) segment is projected to dominate with a 32.1% share in 2025.
• In the drug type segment, the small molecule drugs segment is estimated to lead the market with a 45.5% share in 2025.
• North America is expected to lead the market, holding a share of 41.3% in 2025.
• Asia Pacific is anticipated to be the fastest-growing region, with an estimated market share of 24.3% in 2025.

Market Overview

A key trend in the oral mucositis market revolves around the advancement of targeted therapies and innovative drug delivery systems that aim to minimize the severity and duration of the condition. Additionally, the market is witnessing increased investment in research focusing on preventive and regenerative treatments, including biologics and growth factors. The integration of digital health technologies to monitor treatment outcomes and personalized medicine approaches is shaping future market dynamics, enhancing patient care and improving overall quality of life for affected individuals.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Oral Mucositis Market Insights, By Cause - Dominance of Chemotherapy-Induced Oral Mucositis Driven by Rising Cancer Therapies and Patient Awareness

Out of all possible causes, in 2025, chemotherapy-induced oral mucositis would account for 51.2% of the total share oral mucositis market globally, primarily because chemotherapy is regarded as the main cancer treatment. It is a multi-drug treatment in which the patient is given toxic agents that destroy rapidly dividing cancer cells but at the same time, the agents are also having a negative effect on fast-renewing cells in the oral mucosa.

In August 2025, Chemomouthpiece, LLC, the firm engaged in the manufacture of products related to cancer care, declared that its Chemo Mouthpiece had considerably lessened oral pain and the use of opioids during chemotherapy. The device, which provides cryotherapy, exhibited 46% less pain and 68% lesser use of opioids, giving a more efficient option than the conventional ice chips for the treatment of the side effects of radiotherapy on the mouth and throat.

Oral Mucositis Market Insights, By Treatment Type - Barrier/Coating Agents (Gels, Mouthwashes, Sprays, Films) Lead Treatment Modalities Due to their Direct Protective Action and Versatility

In the global oral mucositis market, barrier/coating agents (gels, mouthwashes, sprays, films) are set to account for 32.1% share in 2025, influenced by their remarkable characteristic of protecting ulcerated mucosal surfaces through shielded layer formation. The physical barrier not only prevents exposure to irritants, microbes, and mechanical trauma of the nerve endings and inflamed tissues but also reduces pain and promotes healing at the same time.

For example, Oncoderm Labs, a U.S.-based company specializing in dermatological oncology products, launched Oral.lytic, a prescription-strength mouthwash designed to treat oral mucositis sores and pain caused by chemotherapy or radiation. The mouthwash is formulated with active ingredients such as lidocaine, nystatin, and diphenhydramine, and is free of artificial dyes and preservatives, making it suitable for sensitive skin and immune systems.

Oral Mucositis Market Insights, By Drug Type - Small Molecule Drugs Lead by Offering Established Efficacy and Broad Applicability

In the global oral mucositis market, small molecule drugs would predominantly be leading with a market share of 45.5% in 2025, because of their proven efficacy, relatively easy development, and widespread use in clinics. Small molecules penetrate tissues effectively as they are of low molecular weight and have a rapid onset of action thus making them very potent in the management of inflammatory and ulcerative states of oral mucositis.

The significant factor which is keeping small molecule agents on the top spot is the wide commercial availability and the clinical ease of handling. These agents are topical analgesics, anti-inflammatories, and antimicrobials which are now considered standard oral care protocols during chemotherapy and radiotherapy furnished with symptom-specific relief of pain, swelling, and infection susceptibility.

Regional Insights

To learn more about this report, Download Free Sample

North America Oral Mucositis Market Analysis and Trends

North America holds the largest share in the global oral mucositis market, with a predicted share of 41.3% in 2025, which is attributed to a well-structured healthcare infrastructure, higher acceptance of advanced medical treatments, and substantial R&D expenditures,. The availability of novel and efficient oral mucositis drugs is also supported by the presence of major pharmaceutical companies and biotech firms, like GlaxoSmithKline, Pfizer, and Amgen, among others.

In April 2024, Napo Pharmaceuticals, a subsidiary of Jaguar Health focusing on novel botanical prescription medicines, expanded its portfolio into cancer-related supportive care following the in-licensing of Gelclair. The company announced plans to commercially launch the FDA-approved Gelclair prescription gel for oral mucositis in the U.S. by Q3 2024.

Asia Pacific Oral Mucositis Market Analysis and Trends

The fastest growth in the oral mucositis market can be observed in Asia Pacific with a predicted market share of 24.3% in 2025 owing to a number of favorable factors. The combination of rising cancer rates, developing healthcare system, and governments’ increased investment in healthcare is perfect for the expansion of this market. China, India, Japan, and South Korea, being the major players in investing massively in oncology care, indirectly increase the demand for oral mucositis management products.

In October 2023, Shilpa Medicare Limited, which is a pharma company with a major focus on innovative healthcare solutions, introduced a new product called ORAAL, an oral mucositis spray in India. The Directorate of Ayurveda and Unani Services has approved ORAAL, which is under a patent till November 2033. The spray is composed of Curcuma Longa, Honey, Glycerin, and Purified Water, and it works quickly to relieve pain and heal mouth sores, with the effects being noticeable in 20 minutes.

Global Oral Mucositis Market Outlook for Key Countries

U.S. Oral Mucositis Market Analysis and Trends

The U.S. is still leading the way in the oral mucositis market thanks to its highly developed healthcare system and the large number of cancer patients that undergo treatment causing mucositis. Major pharmaceutical companies, such as Pfizer, GlaxoSmithKline, and Jazz Pharmaceuticals, are engaged in the active creation of new therapeutic agents and oral care products. The U.S. oral mucositis market is also characterized by clear and supportive regulatory pathways and robust intellectual property protection that helps innovation.

In April 2023, Jaguar Health Inc., a U.S.-based pharmaceutical company specializing in gastrointestinal and supportive care medicines, entered an exclusive five-year in-license agreement with the U.K.-based Venture Life Group PLC for its USFDA-approved oral mucositis prescription product, Gelclair, covering the U.S. oral mucositis market.

Japan Oral Mucositis Market Analysis and Trends

The oral mucositis market in Japan is on a steady growth path because of its modern healthcare system and more elderly people. The government's commitment to cancer treatment and chronic disease management leads to more oral mucositis treatments being demanded. There are also research and development activities of the industry players like Takeda Pharmaceutical and Otsuka Holdings that help to market the introduction of targeted therapies through R&D.

In January 2025, the Tokyo University of Science (TUS), which is recognized as a premier private research university in Japan, disclosed the creation of an adhesive film based on green tea for the treatment of oral mucositis. The new therapy mixes xyloglucan and green tea extract to form mucoadhesive films that offer prolonged relief from oral inflammation resulting from chemotherapy and radiation.

China Oral Mucositis Market Analysis and Trends

China is considered a major and still growing market area in the Asia Pacific. The patient population in the country and the increased access to the healthcare system are the major contributors to the growth of the market. Moreover, the cancer treatment upgrade and healthcare infrastructure improvement initiatives performed by the Chinese government are indirectly supporting oral mucositis management. The local drug manufacturers and global companies like Sun Pharma and Johnson & Johnson have a common goal of making affordable and innovative solutions that cater to the local market.

In January 2025, GenSci, a pharmaceutical company focused on developing innovative oncology treatments, announced the official launch of Episil in China, in partnership with Solasia Pharma K.K. Episil is the only clinically validated mucosal protectant with a registered clinical trial in China, offering hope to cancer patients experiencing oral mucositis due to chemoradiotherapy.

Germany Oral Mucositis Market Analysis and Trends

Germany, being the oral mucositis market leader in Europe, has an effective healthcare system and a powerful pharmaceutical industry as its reasons. The adherence to the regulations outlined by the European Medicines Agency (EMA) is so strict that only those treatments that have been evaluated in the most thorough way are available, and as a result high standards of care are maintained. The major companies, Bayer and Merck, are conducting research and developing oral mucositis products which they will then commercialize.

In July 2022, Destiny Pharma plc, a clinical-stage biotech company, launched a new research program on oral mucositis (OM) in collaboration with experts in Germany and the U.S. The study will test the potential of XF-73 as a preventive treatment for OM in cancer patients, leveraging its antimicrobial properties and excellent safety profile to alleviate pain and improve treatment outcomes for over 2 million affected patients globally.

End User Feedback and Unmet Needs for the Global Oral Mucositis Market

• According to clinicians and oncology centers, the newer oral mucositis treatments have enhanced not only the comfort but also the recovery of patients more so when it comes to cryotherapy devices and mucoadhesive gels which reduce pain and provide support for continuous cancer treatment. Besides, hospitals keep on reporting about better patient compliance and fewer therapy interruptions in the case of advanced mouth rinses and sprays being used effectively.
• However, still, users mention affordability, unequal product access, and lack of personalized options as continuous issues. Hospitals in the less developed areas are facing challenges of high costs and limited awareness programs at the same time. Measures like expanding localized production, improving reimbursement, and developing simpler, more adaptable formulations could be the way to closing these gaps and subsequently enhancing long-term adoption in the global oral mucositis market.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In September 2025, researchers from the University at Buffalo, a leading U.S. public research university known for its advancements in biomedical sciences, introduced an AI model that outperformed conventional methods in predicting infections among stem cell transplant patients with oral mucositis. The AI tool shows strong potential for global clinical integration in oncology care.
• In May 2025, Nanogen Biopharmaceuticals, a European clinical-stage biotech company, reported interim Phase Ib trial results for NG11-2 at ASCO, highlighting its efficacy in preventing or reducing severe radiation-induced oral mucositis in head and neck cancer patients. The findings strengthen the role of topical therapeutics in supportive cancer care worldwide.
• In May 2025, a BMC Cancer-published meta-analysis conducted by an international consortium of oncology researchers confirmed that photobiomodulation therapy (low-level laser therapy) significantly reduces the incidence and severity of oral mucositis in pediatric chemotherapy patients, supporting its global adoption in pediatric oncology protocols.
• In October 2024, Jaguar Health Inc., a U.S.-based pharma firm specializing in supportive care, launched its U.S. FDA-approved oral mucositis product Gelclair in the U.S. through its subsidiary Napo Pharmaceuticals. The gel provides fast, lasting pain relief for oral mucositis, supporting cancer patients’ comfort during treatment.

Top Strategies Followed by Global Oral Mucositis Market Players

• Established Major players monopolize the market through their large investments in research and development (R&D), which they hope will continually result in the production of high-performance products that meet the complex needs of the patients suffering from oral mucositis. The companies are known to tap into their massive resources to come up with advanced drug forms and delivery systems that not only enhance efficacy but also make it easier for the patient to comply.
  • In September 2024, InfuSystem Holdings Inc. and Sanara MedTech Inc. partnered with ChemoMouthpiece LLC for exclusive U.S. distribution of its U.S. FDA-cleared oral cryotherapy device to prevent oral mucositis in chemotherapy patients. The deal enables nationwide supply through SI Healthcare Technologies to about 3,000 cancer centers, aiming to improve patient care and treatment continuity.

• Those at the mid-level of the oral mucositis market tend to take a different approach, but their efforts are no less important, as they focus on providing low-cost items of good quality that are at the same time affordable. This is very crucial since they are targeting consumers who are price-sensitive and are in need of treatments that are both effective and economically accessible
  • In October 2024, ioTech International, a U.S.-based company specializing in molecular iodine oral care solutions, launched ioRinse MR, an advanced and cost-effective oral rinse developed to ease oral mucositis and mouth ulcers in cancer patients undergoing chemotherapy or radiation therapy.

• Small companies, which sometimes do not have such huge resources like the larger ones, use their innovativeness and specialized products to compete in the market. The companies usually highlight the natural or organic ingredients, the innovative delivery systems, or the formulations for specific groups of patients as their distinctive characteristics.
  • For instance, companies like MuReva Phototherapy, a biotech startup developing photobiomodulation-based devices for oral mucositis, and IsoTherapeutics Group, which works on targeted delivery technologies for radiation-induced oral damage, exemplify how small-scale innovators use niche expertise to compete effectively.

Market Report Scope

Oral Mucositis Market Report Coverage

Oral Mucositis Market Dynamics

To learn more about this report, Download Free Sample

Oral Mucositis Market Driver - Rising Cancer Incidence

The rising rate of cancer across the globe is one of the major factors fueling the oral mucositis market, as this disease is one of the most common and most painful side effects of the cancer treatment methods like chemotherapy and radiotherapy. The more cancer patients there are, the more the incidence of oral mucositis goes up, hence the demand for management and treatment options that are effective in the reduction of pain, avoidance of treatment interruptions, and improvement of patient's quality of life. The increasing number of patients who require treatment leads to the necessity of the development of therapeutic methods, which comprise of topical agents, protective coatings, and drug delivery systems that are specially designed for oral mucositis, among others.

In February 2024, the World Health Organization (WHO), a United Nations health agency, and its cancer research arm, the International Agency for Research on Cancer (IARC), released new data highlighting a rising global cancer burden and growing inequities in access to care. The report estimated 20 million new cancer cases and 9.7 million deaths in 2022, with lung, breast, and colorectal cancers leading worldwide. WHO’s survey of 115 countries revealed that only 39% include basic cancer management and 28% provide palliative care under universal health coverage, emphasizing the urgent global need for improved oncology and supportive treatments such as oral mucositis care for cancer patients.

Oral Mucositis Market Opportunity - Development of Combination Therapies

The introduction of combination therapies will be a major factor in the growth of the global oral mucositis market. Oral mucositis, which occurs as a side effect of cancer treatments such as chemotherapy and radiotherapy, has very limited ways of being treated at present. Combination therapies, which include the use of several therapeutic agents or modalities, are likely to have a more comprehensive impact on the complex pathology of oral mucositis than that of monotherapies. The combination of therapies may include anti-inflammatories, growth factors, antioxidants, and pain management drugs, all working together to reduce inflammation, promote tissue healing, and relieve pain.

In July 2025, Taiho Oncology Inc., a U.S.-based biopharmaceutical company focused on cancer therapeutics, and Taiho Pharmaceutical Co. Ltd., its Japan-based parent company specializing in oncology drug development, announced that the U.S. FDA accepted their supplemental new drug application for INQOVI, an oral hypomethylating agent, in combination with venetoclax for treating adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

Analyst Opinion (Expert Opinion)

• The market for oral mucositis is on a growing trend as the use of chemotherapy and radiotherapy in cancer treatments results in higher incidence rates, thereby leading to a greater need for the supportive therapies. With the help of these innovations like low-level laser therapy, mucoadhesive gels, and biologics, the prevention and treatment outcomes have been made much better. Regulatory support from organizations such as MASCC/ISOO, in addition to increasing awareness among oncologists, is elevating the standard of care. However, costly treatment, sporadic insurance coverage, and the lack of extensive clinical evidence supporting new modalities still limit adoption.
• Among these recent developments, we can mention the launch of Gelclair in the U.S. by Jaguar Health and collaborative research under the MASCC/ISOO Oral Care Study Group, which continues to influence worldwide treatment protocols. The MASCC–JASCC–ISOO Annual Meeting (2023, Japan) was one of the events that facilitated the sharing of knowledge and discussions on policies concerning the management of mucositis. This group of initiatives highlights a market that is shifting towards standing on the evidence of innovation, being more accessible and patient quality of life being significantly better.

Market Segmentation

• Cause Insights (Revenue, USD Bn, 2020 - 2032)
  • Chemotherapy-Induced Oral Mucositis
  • Radiotherapy-Induced Oral Mucositis
  • Hematopoietic Stem Cell Transplantation-Induced Oral Mucositis
  • Other Causes
• Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Barrier/Coating Agents (Gels, Mouthwashes, Sprays, Films)
  • Analgesics and Anesthetics (Topical Analgesics, Topical Anesthetics)
  • Anti-Inflammatory Agents (Steroidal, Non-Steroidal)
  • Antimicrobials (Antifungals, Antibacterials)
  • Growth Factors (Palifermin)
  • Cryotherapy Devices (Intraoral Cryotherapy Devices)
  • Nutritional Support Products (Oral Nutritional Supplements)
  • Others
• Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Small Molecule Drugs
  • Biologics
  • Biosimilars
• Severity Grade Insights (Revenue, USD Bn, 2020 - 2032)
  • Mild (Grade 1-2)
  • Severe (Grade 3-4)
• Patient Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Dental Clinics
  • Oncology Hospitals
  • Research and Academic Institutes
  • Homecare Settings
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Amgen Inc
  • Helsinn Healthcare SA
  • Bausch Health Companies Inc
  • Spectrum Pharmaceuticals Inc
  • BioAlliance Pharma SA
  • STADA Arzneimittel AG
  • Soligenix Inc
  • OraPharma Inc
  • Innovation Pharmaceuticals Inc
  • EpicentRx Inc
  • Galera Therapeutics Inc
  • Pfizer Inc
  • Merck & Co
  • Biocon Limited
  • OncoZenge AB

Sources

Primary Research Interviews

• Industry Stakeholders
  • Oncologists
  • Dentists
  • Palliative care specialists
• End Users
  • Cancer patients undergoing chemotherapy or radiotherapy
  • Caregivers and family members of affected patients

Government and International Databases

• National Cancer Institute (NCI)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)

Trade Publications

• Journal of Clinical Oncology
• The Lancet Oncology
• Cancer Treatment Reviews
• Oral Oncology
• Supportive Care in Cancer
• European Journal of Cancer

Academic Journals

• Journal of Oral Pathology & Medicine
• International Journal of Radiation Oncology, Biology, Physics
• European Journal of Cancer Care
• Journal of Pain and Symptom Management
• British Journal of Cancer
• Journal of Clinical Nursing

Reputable Newspapers

• The New York Times
• The Guardian
• The Times of India
• The Washington Post
• Le Monde
• The Hindu

Industry Associations

• American Society of Clinical Oncology (ASCO)
• European Society for Medical Oncology (ESMO)
• American Dental Association (ADA)
• International Society of Oral Oncology (ISOO)
• European Association for Cancer Research (EACR)
• American Association for Cancer Research (AACR)

Public Domain Resources

• National Library of Medicine (NLM)
• Open Access Journals (e.g., PLOS ONE)
• National Institute of Dental and Craniofacial Research (NIDCR)
• Cochrane Library

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years